S1438
Sulindac sulfone
≥94% (HPLC), (solid or powder)
别名:
(Z)-5-Fluoro-2-methyl-1-[p-(methylsulfonyl)benzylidene]indene-3-acetic acid
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H17FO4S
化学文摘社编号:
分子量:
372.41
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
InChI
1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9+
SMILES string
CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C\c3ccc(cc3)S(C)(=O)=O
InChI key
MVGSNCBCUWPVDA-RQZCQDPDSA-N
assay
≥94% (HPLC)
form
(solid or powder)
color
, Light Yellow to Dark Yellow
solubility
DMSO: >25 mg/mL, ethanol: 3 mg/mL (warm), acetone: 5 mg (plus 0.1 ml)
originator
Merck & Co., Inc., Kenilworth, NJ, U.S.
Quality Level
Application
Human endothelial cells, HMEC-1 were treated with Sulindac sulfone and the effect on cell survival was studied by MTT assay.
Biochem/physiol Actions
Metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. Inhibits the development and induces regression of premalignant adenomatous polyps.
Sulindac sulfone is non-steroidal anti-inflammatory drug and an analgesic that has antiproliferative and apoptotic effects. It inhibits the expression and activity of cyclooxygenase-2 in human colon cancer cells1,2 and reduces tumor burden in adenomatous polyposis patients.3
Features and Benefits
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Preparation Note
Sulindac sulfone yields clear, light yellow to dark yellow solution in acetone at 50 mg/ml.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Jin Kyung Lee et al.
The Journal of pharmacology and experimental therapeutics, 334(2), 410-418 (2010-05-01)
Sulindac is a commonly used nonsteroidal anti-inflammatory drug. This study tested the hypothesis that sulindac-mediated drug-drug interactions and/or hepatotoxicity may be caused, in part, by inhibition of proteins responsible for the hepatic transport of drugs and/or bile acids by sulindac
Tien Hoang et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 1(3), 218-225 (2007-04-06)
The study was designed to evaluate the safety and efficacy of exisulind, a selective apoptotic antineoplastic drug, in combination with gemcitabine as second-line therapy in patients with progressing advanced non-small cell lung cancer. Patients whose disease progressed more than 3
Steven Attia et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 3(9), 1018-1025 (2008-09-02)
Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC). Vinorelbine is safe and effective in older patients with advanced NSCLC. We assessed these agents together as palliative treatment for older patients with advanced NSCLC. Chemotherapy-naive
Jun-Yang Liou et al.
Cancer research, 67(7), 3185-3191 (2007-04-06)
To determine the role of 14-3-3 in colorectal cancer apoptosis induced by nonsteroidal anti-inflammatory drugs (NSAIDs), we evaluated the effects of sulindac on 14-3-3epsilon protein expression in colorectal cancer cells. Sulindac sulfide inhibited 14-3-3epsilon proteins in HT-29 and DLD-1 cells
Gregory A Masters et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 1(7), 673-678 (2007-04-06)
Carboplatin and gemcitabine are one standard regimen for patients with advanced non-small cell lung cancer (NSCLC). The oral proapoptotic agent exisulind is a cyclic guanosine monophosphate phosphodiesterase that increases apoptosis in vitro. We performed a phase II trial of carboplatin
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
相关内容
Instructions
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持